Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

被引:187
作者
De Hert, Marc [1 ]
Schreurs, Vincent [1 ]
Sweers, Kim [1 ]
Van Eyck, Dominique [1 ]
Hanssens, Linda [2 ]
Sinko, Sebastjan [3 ]
Wampers, Martien [1 ]
Scheen, Andre [4 ]
Peuskens, Joseph [1 ]
van Winkel, Ruud [1 ,5 ]
机构
[1] Katholieke Univ Leuven, UPC, B-3070 Kortenberg, Belgium
[2] Univ Liege, Dept Epidemiol & Publ Hlth, B-4000 Liege, Belgium
[3] Univ Clin Ctr Maribor, Dept Psychiat, Maribor, Slovenia
[4] Univ Liege, CHU Sart Tilman, Dept Diabet Nutr & Metab Disorders, B-4000 Liege, Belgium
[5] Maastricht Univ, Dept Psychiat & Neuropsychol, EURON, S Limburg Mental Hlth Res & Teaching Network, Maastricht, Netherlands
关键词
schizophrenia; first episode; metabolic syndrome; physical health;
D O I
10.1016/j.schres.2008.01.028
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of MetS in patients with schizophrenia at the onset of the disorder and specifically no data on patients treated in the era when only first-generation antipsychotics were available. Methods: Data from a historic cohort of consecutively admitted first-episode patients with schizophrenia treated with first-generation antipsychotics (FGAs) were compared with an age and sex matched series of consecutive first-episode patients treated only with second-generation antipsychotics (SGAs). Rates of MetS were compared at baseline and after on average 3 years of treatment exposure. Results: At first episode there was no difference in the prevalence of MetS between the historic and the current cohort. Rates of MetS increased over time in both groups, but patients started on SGAs had a three times higher incidence rate of MetS (Odds Ratio 3.6, CI 1.7-7.5). The average increase in weight and body mass index was twice as high in patients started on SGA. The difference between the FGA and SGA group was no longer significant when patients started on clozapine and olanzapine were excluded. Conclusion: Rates of MetS at the first episode of schizophrenia today are not different from those of patients 15 to 20 years ago. This finding counters the notion that the high rates of metabolic abnormalities in patients with schizophrenia currently reported are mainly due to lifestyle changes over time in the general population. Some SGAs have a significantly more negative impact on the incidence of MetS compared to FGAs in first-episode patients. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:295 / 303
页数:9
相关论文
共 68 条
  • [1] The distribution of body mass index among individuals with and without schizophrenia
    Allison, DB
    Fontaine, KR
    Heo, M
    Mentore, JL
    Cappelleri, JC
    Chandler, LP
    Weiden, PJ
    Cheskin, LJ
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (04) : 215 - 220
  • [2] Allison DB, 2001, J CLIN PSYCHIAT, V62, P22
  • [3] Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up
    Attux, Cecilia
    Quintana, Maria Ines
    Chaves, Ana Cristina
    [J]. REVISTA BRASILEIRA DE PSIQUIATRIA, 2007, 29 (04) : 346 - 349
  • [4] Antipsychotic medications: compliance and attitudes towards treatment
    Awad, AG
    [J]. CURRENT OPINION IN PSYCHIATRY, 2004, 17 (02) : 75 - 80
  • [5] The prevalence of the metabolic syndrome in patients with schizoaffective disorder - bipolar subtype
    Basu, R
    Brar, JS
    Chengappa, KNR
    John, V
    Parepally, H
    Gershon, S
    Schlicht, P
    Kupfer, DJ
    [J]. BIPOLAR DISORDERS, 2004, 6 (04) : 314 - 318
  • [6] Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study
    Bobes, Julio
    Arango, Celso
    Aranda, Pedro
    Carmena, Rafael
    Garcia-Garcia, Margarida
    Rejas, Javier
    [J]. SCHIZOPHRENIA RESEARCH, 2007, 90 (1-3) : 162 - 173
  • [7] Causes of the excess mortality of schizophrenia
    Brown, S
    Inskip, H
    Barraclough, B
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2000, 177 : 212 - 217
  • [8] Mortality in schizophrenia and schizoaffective disorder: An Olmsted county, Minnesota cohort: 1950-2005
    Capasso, Rebecca M.
    Lineberry, Timothy W.
    Bostwick, J. Michael
    Decker, Paul A.
    Sauver, Jennifer St.
    [J]. SCHIZOPHRENIA RESEARCH, 2008, 98 (1-3) : 287 - 294
  • [9] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [10] Characterizing Coronary Heart Disease Risk in Chronic Schizophrenia: High Prevalence of the Metabolic Syndrome
    Cohn, Tony
    Prud'homme, Denis
    Streiner, David
    Kameh, Homa
    Remington, Gary
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2004, 49 (11): : 753 - 760